<SEC-DOCUMENT>0001564590-19-037287.txt : 20191022
<SEC-HEADER>0001564590-19-037287.hdr.sgml : 20191022
<ACCEPTANCE-DATETIME>20191022084208
ACCESSION NUMBER:		0001564590-19-037287
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20191022
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191022
DATE AS OF CHANGE:		20191022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		191160634

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hrtx-8k_20191022.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-22T01:30:13.3182901+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 3bd10fa5126c4a3b8816b0e4ce0e5afd -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:hrtx="http://www.herontx.com/20191022" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
hrtx-8k_20191022.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000818033_20191022_20191022">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000818033_20191022_20191022">HERON THERAPEUTICS, INC. /DE/</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000818033_20191022_20191022">0000818033</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="hrtx-20191022.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000818033_20191022_20191022">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-22</xbrli:startDate>
					<xbrli:endDate>2019-10-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt #000000;padding-bottom:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000818033_20191022_20191022">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000818033_20191022_20191022" format="ixt:datemonthdayyearen">October 22, 2019</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000818033_20191022_20191022">001-33221</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:29.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000818033_20191022_20191022">94-2875566</ix:nonNumeric></p></td>
</tr>
<tr style="height:21.15pt;">
<td valign="top" style="width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:29.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:56.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000818033_20191022_20191022">4242 Campus Point Court</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0000818033_20191022_20191022">Suite 200</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0000818033_20191022_20191022">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressStateOrProvince" contextRef="C_0000818033_20191022_20191022">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0000818033_20191022_20191022">92121</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:56.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code <ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0000818033_20191022_20191022">(858)</ix:nonNumeric> <ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0000818033_20191022_20191022">251-4400</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39.92%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:22.6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:34.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0000818033_20191022_20191022">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0000818033_20191022_20191022">HRTX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:34.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Emoji;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000818033_20191022_20191022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Emoji;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt #000000;padding-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01 Other Events.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_2">On October 22, 2019, Heron Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing that <span style="color:#1E1E1E;">the U.S. Food and Drug Administration has approved the Company&#8217;s supplemental New Drug Application for CINVANTI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (aprepitant) injectable emulsion for intravenous (IV) use, expanding the recommended dosage to include the 130 mg single-dose regimen for patients receiving moderately emetogenic chemotherapy</span>, as described in the press release furnished herewith as Exhibit 99.1.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01 Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:89%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrtx-ex991_6.htm"><span style="text-decoration:underline;">Press Release, dated October 22, 2019</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: October 22, 2019</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Szekeres</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Szekeres</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, General Counsel,<br />Business Development and Corporate Secretary</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hrtx-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrtx-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g22rsonocdq5000001.jpg" title="" alt="" style="width:156px;height:68px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk18407375"></a>Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN DIEGO, Calif. -- (PR NEWSWIRE) &#8211; October 22, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX),<font style="color:#1E1E1E;"> a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron&#8217;s supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion for intravenous (IV) use. The sNDA requested FDA approval to expand the recommended dosage to include the 130 mg single-dose regimen for patients receiving MEC. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI is the first and only IV formulation of a substance P/neurokinin-1 (NK<sub style="font-size:85%; vertical-align:bottom">1</sub>)<sub style="font-size:85%; vertical-align:bottom"> </sub>receptor antagonist (RA) that is free of synthetic surfactants, including polysorbate 80, and that is approved for use as a 2-minute IV injection (also referred to as an IV push). CINVANTI is indicated for the prevention of acute and delayed <font style="color:#000000;">chemotherapy-induced nausea and vomiting</font> (CINV) following both highly emetogenic cancer chemotherapy (HEC) and MEC. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK<sub style="font-size:85%; vertical-align:bottom">1</sub><sub style="font-size:85%; vertical-align:bottom"> </sub>RA to significantly reduce CINV in both the acute phase (0&#8211;24 hours after chemotherapy) and the delayed phase (24&#8211;120 hours after chemotherapy).</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI was initially approved based on data demonstrating the bioequivalence of CINVANTI to EMEND IV<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;&#160;</sup>(fosaprepitant), supporting its efficacy for the prevention of acute and delayed CINV following HEC and MEC. Results from two pivotal, randomized, cross-over, bioequivalence studies of CINVANTI and EMEND IV showed subjects receiving CINVANTI reported fewer adverse events than those receiving EMEND IV, including substantially fewer infusion-site reactions. In February 2019, the FDA approved Heron&#8217;s sNDA to expand the administration of CINVANTI beyond the already approved administration method (a 30-minute IV infusion) to include a 2-minute IV injection (also referred to as an IV push). This 2-minute IV push for CINVANTI was approved based on a third study demonstrating bioequivalence and a comparable safety profile to CINVANTI given as a 30-minute IV infusion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CINVANTI label expansion standardizes the CINVANTI 130 mg single-dose regimen for patients receiving HEC and/or MEC as an injection over 2 minutes or an infusion over 30 minutes, further simplifying dosing and administration and eliminating the need to take oral aprepitant on Days 2 and 3 following MEC administration. Furthermore, this label expansion builds on the prior label expansion that introduced the 2-minute IV push, which enables physicians to leverage the operational advantages of this method of administration and contributes to a reduction in total patient time spent at the infusion site.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&#8220;This most recent label expansion to offer a simplified dosing regimen for MEC adds to the important advantages CINVANTI provides to patients as the only FDA-approved, IV NK<sub style="font-size:85%; vertical-align:bottom">1</sub> RA available as a convenient 2-minute IV push for MEC and HEC,&#8221; said Rudolph M. Navari, M.D., Ph.D., University of Alabama, Birmingham School of Medicine, Division of Hematology and Oncology. <font style="color:#000000;">&#8220;The simplified dosing in MEC removes the need for patients to take oral aprepitant </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g22rsonocdq5000001.jpg" title="" alt="" style="width:156px;height:68px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">on Days 2 and 3, which </font><font style="color:#000000;">can</font><font style="color:#000000;"> improve compliance and reduce costs. These benefits continue to improve the overall patient experience with CINVANTI.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About CINVANTI (aprepitant) injectable emulsion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC, including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of MEC. CINVANTI is an IV formulation of aprepitant, an NK<sub style="font-size:85%; vertical-align:bottom">1</sub> RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK<sub style="font-size:85%; vertical-align:bottom">1</sub>&#160;RA to significantly reduce nausea and vomiting in both the acute phase (0&#8211;24 hours after chemotherapy) and the delayed phase (24&#8211;120 hours after chemotherapy). The&#160;FDA-approved dosing administration included in&#160;the United States&#160;prescribing information for CINVANTI is a 30-minute IV infusion or a 2-minute IV injection.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see full prescribing information at&#160;<font style="color:#1D4095;text-decoration:underline;">www.CINVANTI.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Important Safety Information&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contraindications</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI is contraindicated in patients with hypersensitivity to any of the components of CINVANTI.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent use of pimozide with CINVANTI is contraindicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Warnings and Precautions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Clinically Significant CYP3A4 Drug Interactions</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;font-size:11pt;">Use of </font><font style="font-family:Arial;font-size:11pt;color:#000000;">CINVANTI </font><font style="font-family:Arial;font-size:11pt;">with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-size:10pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-size:10pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:10pt;"><font style="font-family:Arial;font-size:11pt;">Use of pimozide with CINVANTI is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;font-size:11pt;">Use of CINVANTI with strong or moderate CYP3A4 inhibitors (</font><font style="font-style:italic;font-family:Arial;font-size:11pt;">e.g.</font><font style="font-family:Arial;font-size:11pt;">, ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to CINVANTI.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#1E1E1E;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#1E1E1E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;font-size:11pt;">Use of CINVANTI with strong CYP3A4 inducers (</font><font style="font-style:italic;font-family:Arial;font-size:11pt;">e.g.</font><font style="font-family:Arial;font-size:11pt;">, rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of </font><font style="font-family:Arial;font-size:11pt;color:#000000;">CINVANTI</font><font style="font-family:Arial;font-size:11pt;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g22rsonocdq5000001.jpg" title="" alt="" style="width:156px;height:68px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-style:italic;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Hypersensitivity Reaction</font><font style="font-style:italic;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">s</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of CINVANTI have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. If hypersensitivity reactions occur, discontinue CINVANTI. Do not reinitiate CINVANTI in patients who experience these symptoms with previous use.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Decrease in INR with Concomitant Warfarin</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-administration of CINVANTI with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of CINVANTI with each chemotherapy cycle.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Risk of Reduced Efficacy of Hormonal Contraceptives</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of CINVANTI. Advise patients to use effective alternative or back-up methods of non-hormonal contraception during treatment with CINVANTI and for 1 month following administration of CINVANTI or oral aprepitant, whichever is administered last.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Use in&#160;Specific&#160;Populations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avoid use of CINVANTI in pregnant women as alcohol is an inactive ingredient for CINVANTI. There is no safe level of alcohol exposure in pregnancy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Adverse Reactions</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most common adverse reactions are:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Single-dose fosaprepitant with MEC (&#8805;2%): fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">3-day oral aprepitant with MEC (&#8805;1% and greater than standard therapy): fatigue and eructation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Arial;">Single-dose fosaprepitant with HEC: generally similar to 3-day oral aprepitant. In addition, infusion site reactions (3%) occurred.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Arial;font-size:11pt;">Single-dose CINVANTI (&#8805;2%): headache and fatigue. The safety profile of CINVANTI in healthy subjects who received a single 2-minute injection was similar to that seen with a 30-minute infusion.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About&#160;Heron Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics<font style="color:#1E1E1E;">, Inc.&#160;is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. For more information, visit&#160;</font><font style="color:#1D4095;text-decoration:underline;">www.herontx.com</font><font style="color:#1E1E1E;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g22rsonocdq5000001.jpg" title="" alt="" style="width:156px;height:68px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the commercial opportunity for CINVANTI; and other risks and uncertainties identified in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations and Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1E1E1E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Szekeres<br />Senior VP, General Counsel, Business Development&#160;and Corporate Secretary<br />Heron Therapeutics, Inc.<br /><font style="color:#1D4095;text-decoration:underline;">dszekeres@herontx.com</font>&#160;<br />858-251-4447</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g22rsonocdq5000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22rsonocdq5000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0#$17AI9@  34T *@    @  P$[  (
M   .    ,H=I  0    !    0)R=  $    <    H     !2>6%N($\G0F%N
M;F]N   $D ,  @   !0   !VD 0  @   !0   "*DI$  @    ,T,0  DI(
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M]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$
M @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S
M4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H
M# ,!  (1 Q$ /P#Z1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HR/6F32K!"TCG"J
M,FOEOQMXUUC4?$USLO)8(X9&1%BD*C&>O%=>%PLL1)I.UC&K55-79]39'J*6
MOCZS\0ZS)?0*-2NR3(N!YS>M?6ND^=_9-M]H_P!9Y:Y_*JQ6$>&M=WN*E652
M^A<HHHKB-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'R*/^%G>*_^@G)_WR*/[-J]T'UJ'8^DJ*^;?^%G>*_^@G)_WR*/^%G>*_\
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M\.?\^$7Y4?\ "M_#G_/A%^5=911[:K_,PY(]CD_^%;^'/^?"+\J/^%;^'/\
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M4'M<G_T.OIOPS_R +?!!^7L:]?,'RTHQ6QQX?63;-:BBBO%.X**** "BBB@
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M0HHHH **** "BBB@ HHHH **** "BBB@#B?BW_R3ZY_ZZI_.O./@O_R.S?\
M7N]>C_%O_DGUS_UU3^=><?!?_D=F_P"O=Z]C#_[E/YG'4_C1/?:***\<[ HH
MHH *.M%% '/^)O!^F^);$Q7$2HXSM=  :\,\6^!=3\*72R*&DA<Y1XR21]<5
M])U'-;Q7$92>-74C&&&:[,/BYT=-T8U*,9^IX3X4^*^H:4\-EJ8$EHO!;&6%
M>W:?JEIJ5O'+:SQOO4-M##(_"O,_%_P@.H:C]J\/O' C*3(DA/+>U><V%WKW
M@_51=JDT)C8QDNAVMSTYKLE1HXI<U)V?8Q4YTG:>Q]/45P_A'XF:;XCG^R3
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M-)%VR*K#T89IU% 'F_BWX46>JF6[TLF*Z;)V9PIKQF:#4] OF4^? \4GWAN
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M1!:KMC'04UAVL2ZU^EAJB_;NK?I8LT445UG0%,G_ ./>3_</\J?2$;E(/0T
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M[LVHT52C;=A11174;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>hrtx-20191022.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-22T01:30:13.3182901+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 3bd10fa5126c4a3b8816b0e4ce0e5afd -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:hrtx="http://www.herontx.com/20191022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.herontx.com/20191022" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.herontx.com/20191022/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20191022_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20191022_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>hrtx-20191022_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-22T01:30:13.3182901+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 3bd10fa5126c4a3b8816b0e4ce0e5afd -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>hrtx-20191022_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-22T01:30:13.3182901+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : 3bd10fa5126c4a3b8816b0e4ce0e5afd -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.herontx.com/20191022/role/TemplateLink" xlink:href="hrtx-20191022.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hrtx-20191022.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>hrtx-8k_20191022_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrtx-20191022.xsd" xlink:type="simple"/>
    <context id="C_0000818033_20191022_20191022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
        </entity>
        <period>
            <startDate>2019-10-22</startDate>
            <endDate>2019-10-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000818033_20191022_20191022" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0000818033_20191022_20191022" id="F_000003">HERON THERAPEUTICS, INC. /DE/</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0000818033_20191022_20191022" id="F_000004">0000818033</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000818033_20191022_20191022" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000818033_20191022_20191022" id="F_000002">2019-10-22</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000818033_20191022_20191022" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000818033_20191022_20191022" id="F_000006">001-33221</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000818033_20191022_20191022" id="F_000008">94-2875566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000818033_20191022_20191022" id="F_000009">4242 Campus Point Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000818033_20191022_20191022" id="F_000010">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000818033_20191022_20191022" id="F_000011">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000818033_20191022_20191022" id="F_000012">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000818033_20191022_20191022" id="F_000013">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000818033_20191022_20191022" id="F_000014">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000818033_20191022_20191022" id="F_000015">251-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000818033_20191022_20191022" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000818033_20191022_20191022" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000818033_20191022_20191022" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000818033_20191022_20191022" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000818033_20191022_20191022" id="F_000020">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000818033_20191022_20191022" id="F_000021">HRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000818033_20191022_20191022" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000818033_20191022_20191022" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>8
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "hrtx-8k_20191022.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "hrtx-8k_20191022.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrtx-20191022_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrtx-20191022_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hrtx-20191022.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hrtx",
   "nsuri": "http://www.herontx.com/20191022",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hrtx-8k_20191022.htm",
      "contextRef": "C_0000818033_20191022_20191022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hrtx-8k_20191022.htm",
      "contextRef": "C_0000818033_20191022_20191022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "verboseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hrtx-8k_20191022.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.herontx.com/20191022/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="hrtx-8k_20191022.htm">hrtx-8k_20191022.htm</File>
    <File>hrtx-20191022.xsd</File>
    <File>hrtx-20191022_lab.xml</File>
    <File>hrtx-20191022_pre.xml</File>
    <File>hrtx-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MQYXRB%H 4_/$>!B[%LZ &4:8?/XNH%V(I?HGMG2 '9-C=DMJ&(9Z6)7<M(.
MMZ?'E[)NY?I,NC<X_<I.TB'BFITFOZ[N[C</3#5<W%:"5TVSX3?R4LBKYGUV
M_>%W%O;!NJW[Q\8G0=7"K[M07U!+ P04    " !#159/F5R<(Q &  "<)P
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M%[:MAF)TZ!C9C85V-E7[VW]02P,$%     @ 0T563TUMP:)Y @  6 8  !0
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M#?_)\@M02P$"% ,4    " !#159/'R// \     3 @  "P
M@ $     7W)E;',O+G)E;'-02P$"% ,4    " !#159/)^B'#H(   "Q
M$               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M $-%5D]!^:3+[@   "L"   1              "  9D!  !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( $-%5D^97)PC$ 8  )PG   3
M  "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 0T563YC@
M/YBK @  ^0L  !@              ( !]P@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( $-%5D]-;<&B>0(  %@&   4
M  "  =@+  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( $-%5D^Z
MH3F*UP$  #(&   -              "  8,.  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ 0T563Q9M(W]# 0  / (   \              ( !A1   'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $-%5D__P"8(O0   (4"   :
M          "  ?41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( $-%5D\+C]@#(0$  %<$   3              "  >H2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (  #P4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6603586672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 22,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HERON THERAPEUTICS, INC. /DE/<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-2875566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4242 Campus Point Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001564590-19-037287-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-037287-xbrl.zip
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MGK&7X6ZE+6>:%;F8*NZ+ZQ]02P,$%     @ 0T563VR/_><Q!P  ATP  !4
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MGV9IWL307^OKW96$/WZ>E2*S(B%,$934TE*'&2\$3R"YK@F<5G7C5J=FZN5
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MJ27VYHD;<21_WRH]A9/??/KT/U!+ P04    " !#159/36I$*@P%  "F+0
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MMQ'38^CDOVNUB"?0+J=$KL[#><1$89!;D(":B#8,CY9_L#/!'B@7!K/'QMR
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MO1(M=BH5Y[!CLY+';%:F77^ZIR(:2][K:[+G[9LNPGC#D 4!&Y///*2AQVE
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M,#$Y,3 R,E]L86(N>&UL4$L! A0#%     @ 0T563TUJ1"H,!0  IBT  !4
M             ( !80P  &AR='@M,C Q.3$P,C)?<')E+GAM;%!+ 0(4 Q0
M   ( $-%5D^093*#GA   (6(   4              "  : 1  !H<G1X+3AK
M7S(P,3DQ,#(R+FAT;5!+ 0(4 Q0    ( $-%5D\&P73Q]!,  (5\   0
M          "  7 B  !H<G1X+65X.3DQ7S8N:'1M4$L%!@     %  4 10$
' )(V      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
